Related Experiment Video
Updated: Sep 20, 2025
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.9K
Novel Therapeutics for Advanced Differentiated Thyroid Cancer
Leedor Lieberman1, Francis Worden2
1Department of Metabolism, Endocrinology and Diabetes, University of Michigan, Lobby C #1300, 4029 Avenue Maria Drive, Ann Arbor, MI 48105, USA.
Summary
New treatments for radioactive iodine-refractory differentiated thyroid cancer (DTC) are emerging. These include targeted therapies and immunotherapy, offering new hope beyond traditional kinase inhibitors for advanced DTC.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) presents evolving treatment challenges.
- Current first-line therapies like multitargeted tyrosine kinase inhibitors have significant adverse effects.
- Understanding cancer genomics is driving the development of novel therapeutic strategies.
Purpose of the Study:
- To review the evolving landscape of treatments for RAI-refractory DTC.
- To highlight the role of emerging targeted therapies and immunotherapy.
- To discuss advancements in redifferentiation of iodine avidity.
Main Methods:
- Review of current literature on RAI-refractory DTC treatments.
- Analysis of next-generation sequencing data for targeted therapeutic identification.
- Exploration of ongoing investigations into novel treatment modalities.
Main Results:
- Multitargeted tyrosine kinase inhibitors remain a first-line option but with limitations.
- Targeted therapies, including MEK1/2, BRAF, RET, and NTRK inhibitors, are emerging based on genomic profiling.
- Immunotherapy is being investigated as a potential treatment avenue.
Conclusions:
- The treatment paradigm for RAI-refractory DTC is shifting towards precision medicine.
- Targeted therapies offer potential for improved efficacy and reduced toxicity.
- Further research into immunotherapy and redifferentiation strategies is crucial for advancing patient care.
Related Concept Videos
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
01:27Tumor Immunotherapy
677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
01:20Synthesis and Regulation of Thyroid Hormones
5.2K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.2K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K